Sartorius AI Stock Analysis
Want to see DE:SRT full AI Analyst Report?
Sartorius (SRT) AI Stock Analysis
Sartorius
(XETRA:SRT)
The score is driven primarily by stable-but-not-peak financials (solid operating margins and improving free cash flow, but thin net margins, meaningful leverage, and weaker cash conversion). Technicals are supportive with a clear uptrend, though momentum is overbought. The latest earnings call was constructive with reaffirmed/raised guidance and improving profitability, but valuation is a major constraint due to a very high P/E and minimal yield.
Sartorius (SRT) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 15.52B
- Dividend Yield
- 0.32%
- Average Volume (3M)
- 3,627
- Price to Earnings (P/E)
- 71.4
- Beta (1Y)
- 1.16
- Revenue Growth
- 4.19%
- EPS Growth
- 63.32%
- Country
- Germany
- Employees
- 14,042
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Instruments & Supplies
Sartorius Business Overview & Revenue Model
Company Description
Sartorius AG, founded in Göttingen, Germany in 1870, is a global supplier of advanced bioprocess solutions, laboratory products, and associated services. The company's diverse portfolio encompasses several critical areas: For biosensing and detection...
How the Company Makes Money
Sartorius makes money by selling products and services used repeatedly in bioprocessing and laboratory operations, with a business mix that typically combines (a) recurring consumables revenue and (b) capital equipment and systems revenue, complement...
Sartorius Earnings Call Summary
The call was strongly positive overall. Management reported broad-based sales growth, continued recovery in equipment and non-recurring business, expanding margins, substantially higher free cash flow, lower leverage, and upgraded LPS guidance. The main challenges were tariff-related growth headwinds, pull-forward and timing effects in LPS, ATS project delays, difficult Q4 comparisons, FX pressure, and continued cyclicality in equipment demand. These lowlights were acknowledged but did not outweigh the operational, financial, and balance-sheet improvements.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
The company confirmed full-year operational sales growth broadly around the midpoint of the 5%-9% range for the group, 6%-10% for Bioprocess Solutions, and around the upper end of the 2%-6% range for Lab Products & Services; including customer compensation for tariff surcharges, growth in constant currencies is expected to be in the lower half of the respective guidance ranges for the group and BPS, and around the upper end of the range for LPS. Underlying EBITDA margin is expected to be slightly above 30% for the group, slightly above 32% for Bioprocess Solutions, and slightly above 21% for LPS. The full-year CapEx ratio expectation was lowered from around 12.5% to around 12%, net debt to underlying EBITDA remains expected at slightly above three times at year-end, MatTek’s contribution remains approximately 30 basis points for the group and 1.5 percentage points for LPS, tariff refund applications were approximately EUR 40 million with around EUR 31 million received by the end of September and the outstanding EUR 9 million expected by year-end, and FX is modeled as a headwind of slightly more than one percentage point on reported revenue growth for the full year and a tailwind of slightly below two percentage points in Q4. For Sartorius Stedim Biotech, operational growth is expected around the midpoint of the 6%-10% range, reported growth in constant currencies including customer compensation is expected to be in the lower half of this range, underlying EBITDA margin is expected to be slightly above 31%, the full-year CapEx ratio expectation was lowered from around 13.3% to around 13%, net debt to underlying EBITDA remains expected at slightly above two times at year-end, and FX headwind should be approximately 1.2 percentage points on reported revenue growth for the full year and a tailwind of approximately 1.7 percentage points in Q4.
Sartorius Financial Statement Overview
Summary
Stable but not peak performance. Revenue growth is modest (+2.32%) with solid operating profitability (TTM operating margin ~17.8%, EBITDA margin ~29.5%), but net margin is thin (~5.3%) versus 2021–2022. Leverage remains meaningful (debt-to-equity ~1.33) and cash conversion is a watch item (FCF to net income ~0.46) despite a rebound in free cash flow (€339M, +15.8%).
Income Statement
66PositiveBalance Sheet
58NeutralCash Flow
61Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.66B | 3.54B | 3.38B | 3.40B | 4.17B | 3.45B |
| Gross Profit | 1.66B | 1.64B | 1.52B | 1.57B | 2.20B | 1.84B |
| EBITDA | 1.08B | 1.07B | 786.80M | 873.20M | 1.54B | 945.12M |
| Net Income | 218.40M | 154.90M | 84.00M | 205.20M | 913.10M | 426.98M |
Balance Sheet | ||||||
| Total Assets | 9.67B | 9.72B | 10.10B | 9.76B | 6.98B | 5.70B |
| Cash, Cash Equivalents and Short-Term Investments | 230.70M | 541.40M | 828.70M | 394.20M | 196.80M | 360.99M |
| Total Debt | 3.91B | 4.45B | 4.56B | 5.31B | 2.54B | 2.08B |
| Total Liabilities | 5.53B | 5.85B | 6.21B | 7.00B | 4.32B | 3.98B |
| Stockholders Equity | 2.93B | 2.71B | 2.76B | 2.07B | 1.99B | 1.26B |
Cash Flow | ||||||
| Free Cash Flow | 351.70M | 214.10M | 566.30M | 293.90M | 211.60M | 458.65M |
| Operating Cash Flow | 750.60M | 656.00M | 976.20M | 853.60M | 734.20M | 865.81M |
| Investing Cash Flow | -392.10M | -513.50M | -425.80M | -2.82B | -1.13B | -569.61M |
| Financing Cash Flow | -524.30M | -410.60M | -128.30M | 2.17B | 209.90M | -165.18M |
Sartorius Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:SRT, the sentiment is Positive. The current price of 225.50 is above the 20-day moving average (MA) of 224.60, above the 50-day MA of 209.37, and above the 200-day MA of 188.98, indicating a bullish trend. The MACD of 5.35 indicates Positive momentum. The RSI at 57.00 is Neutral, neither overbought nor oversold. The STOCH value of 43.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:SRT.
Sartorius Peers Comparison
Overall Rating
DE:G1A80Outperform
DE:EVK64Neutral
DE:SRT62Neutral
DE:PFV59Neutral
DE:SBS54Neutral
DE:GXI52Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 80Outperform | EUR 11.39B | 26.01 | 17.46% | 1.84% | 5.37% | 9.46% | |
| 64Neutral | EUR 9.94B | 56.31 | 2.16% | 4.69% | 1.98% | 83.13% | |
| 62Neutral | EUR 17.83B | 71.36 | 7.81% | 0.32% | 4.19% | 63.32% | |
| 59Neutral | EUR 1.57B | 23.20 | 12.29% | 4.59% | 0.35% | 116.73% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 54Neutral | EUR 339.15M | -7.99 | -18.69% | 2.15% | ― | ― | |
| 52Neutral | EUR 1.07B | -2.68 | -32.84% | 0.13% | 8.90% | -609.05% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:SRT | Sartorius (0NIQ) | 225.50 | 44.88 | 24.85% | |
| DE:EVK | Evonik Industries AG | 21.32 | 8.76 | 69.69% | |
| DE:G1A | GEA Group AG | 70.50 | 13.68 | 24.07% | |
| DE:GXI | Gerresheimer AG | 31.08 | 6.74 | 27.69% | |
| DE:PFV | Pfeiffer Vacuum Technology | 159.60 | 10.48 | 7.03% | |
| DE:SBS | STRATEC Biomedical | 27.90 | 7.94 | 39.78% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 27, 2026
